Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
暂无分享,去创建一个
M. Lindegren | S. Holmberg | Jeffrey L. Jones | J. Kaplan | J. Bertolli | T. Frederick | D. Hanson | J. Jones | M. Dworkin
[1] P. Pellett,et al. Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] J. Ward,et al. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. , 1999, AIDS.
[3] H. Amandus,et al. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. , 1999, Journal of acquired immune deficiency syndromes.
[4] J A Fleishman,et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. , 1999, JAMA.
[5] A. Telenti,et al. The New England Jour nal of Medicine DISCONTINUATION OF PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN HIV-1–INFECTED ADULTS TREATED WITH COMBINATION ANTIRETROVIRAL THERAPY , 2022 .
[6] A. Mocroft,et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.
[7] J. Ward,et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
[8] C. Jaspers,et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy , 1999, The Lancet.
[9] J. Ward,et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. , 1998, Journal of acquired immune deficiency syndromes.
[10] D. McCaffrey,et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. , 1998, The New England journal of medicine.
[11] J. Akiyama. Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
[12] B. Yip,et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[14] F. Raffi,et al. Opportunistic infections occurring during highly active antiretroviral treatment , 1998, AIDS.
[15] T. Navin,et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. , 1998, The Journal of infectious diseases.
[16] M. Woods,et al. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection , 1998, AIDS.
[17] J. Kahn,et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.
[18] J. Ward,et al. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. , 1998, The Journal of infectious diseases.
[19] M. Narita,et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. , 1998, American journal of respiratory and critical care medicine.
[20] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[21] J. Oleske,et al. Guidelines for the use of antiretroviral agents in pediatric HIV infection , 1998 .
[22] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[23] N. Letvin,et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease , 1998, The Lancet.
[24] C. Beard,et al. Opportunistic Infections (OIs) as Emerging Infectious Diseases: Challenges Posed by OIs in the 1990s and Beyond , 1998 .
[25] W. Craig,et al. Emerging Infections 2 , 1998 .
[26] M. Jacobson,et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy , 1997, The Lancet.
[27] M Gwinn,et al. Prevalence of HIV infection in the United States, 1984 to 1992. , 1996, JAMA.
[28] H. Barnhart,et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. , 1996, Pediatrics.
[29] R. Chaisson,et al. Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.
[30] J. Neaton,et al. Frequencies of opportunistic diseases prior to death among HIV‐infected persons , 1995, AIDS.
[31] K. Holmes,et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] J. Thornton. Prevalence of HIV infection , 1995, BMJ.
[33] J. Fleishman,et al. Correlates of medical service utilization among people with HIV infection. , 1994, Health services research.
[34] D. Follmann,et al. Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study Group. , 1994, American journal of preventive medicine.
[35] R. Chaisson,et al. Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.
[36] K. Castro,et al. Gender differences in reported AIDS-indicative diagnoses. , 1993, The Journal of infectious diseases.
[37] J. Phair,et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. , 1993, American journal of epidemiology.
[38] C. Reed,et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. , 1992, JAMA.